The 20% stock drop was a market overreaction to expected weak Q4 EPS due to temporary expenses. Lantheus has strong growth potential with key products Pylarify and Definity, supported by government backing. The forward P/E of 13 and projected 15% annual revenue growth suggest the stock is undervalued, presenting a buying opportunity.